William Blair analyst Matt Larew has maintained their neutral stance on AMED stock, giving a Hold rating on August 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Larew has given his Hold rating due to a combination of factors surrounding the recent developments in the proposed acquisition of Amedisys by UnitedHealth. The announcement of a settlement between the Department of Justice and UnitedHealth/Amedisys has led to a rise in Amedisys’s stock price, nearing the agreed deal price of $101. This settlement, which includes a divestiture package, is a significant step towards resolving the disputes that have been ongoing in this acquisition process.
While the settlement awaits final approval, it is seen as the last major hurdle in the acquisition saga. Larew likely considers the current stock price to reflect the anticipated benefits of the acquisition, thus justifying a Hold rating. The expectation that no further obstacles will emerge suggests that the stock is fairly valued at its current level, leading to a recommendation to neither buy nor sell at this time.
In another report released on August 1, TD Cowen also maintained a Hold rating on the stock with a $101.00 price target.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMED in relation to earlier this year.